Nevro (NVRO) Stock Forecast & Price Target

$5.29

+0.09 (+1.73%)

(As of 09/27/2024 ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 14 Analyst Ratings

Sell
3

Hold
11

Buy
0

Based on 14 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 14 analysts, 3 have given a sell rating, and 11 have given a hold rating for NVRO.

Consensus Price Target

$10.63
100.88% Upside

According to the 14 analysts' twelve-month price targets for Nevro, the average price target is $10.63. The highest price target for NVRO is $23.00, while the lowest price target for NVRO is $5.50. The average price target represents a forecasted upside of 100.88% from the current price of $5.29.

NVRO Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	8 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$10.63	$10.63	$19.46	$30.62
Forecasted Upside	100.88% Upside	68.41% Upside	131.13% Upside	59.29% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Nevro Stock vs. The Competition

Type	Nevro	Medical Companies	S&P 500
Consensus Rating Score	1.79	2.78	2.50
Consensus Rating	Reduce	Moderate Buy	Hold
Predicted Upside	100.88% Upside	818.48% Upside	6.14% Upside
News Sentiment Rating	Positive News See Recent NVRO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/9/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$6.89	+21.52%
8/8/2024	Truist Financial 1 of 5 stars		Lower Target	Hold ➝ Hold	$10.00 ➝ $5.50	+13.17%
8/8/2024	Wolfe Research 3 of 5 stars	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $7.00	+41.99%
8/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$11.00 ➝ $8.00	+51.52%
8/7/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$12.00 ➝ $7.00	-19.45%
Who are Nvidia’s New Silent Partners? (Ad) Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024. I call these Nvidia’s “Silent Partners.”
8/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Treybeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$13.00 ➝ $5.50	-36.71%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $9.00	-4.26%
5/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$17.00 ➝ $11.00	+5.97%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$20.00 ➝ $16.00	+20.30%
2/22/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
11/2/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$31.00	-16.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:58 PM ET.

NVRO Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $10.63, with a high forecast of $23.00 and a low forecast of $5.50.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 sell ratings and 11 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NVRO shares.
: According to analysts, Nevro's stock has a predicted upside of 100.88% based on their 12-month stock forecasts.
: Over the previous 90 days, Nevro's stock had 3 downgrades and 2 upgrades by analysts.
: Nevro has been rated by research analysts at Citigroup, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Jovine Was Right in 2008—Will You Listen This Time? (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

This page (NYSE:NVRO) was last updated on 9/28/2024 by MarketBeat.com Staff

From Our Partners